Tag Archives: ANVISA

Brazil Patent Policy: At a Crossroads

Photo By: DigiDreamGrafix.com

The Government of Brazil approaches the patent policy crossroads with two ministries wanting to move in opposite directions.  In the last few months, both the Brazilian Patent Office (INPI) and the Brazilian Regulatory Authority (ANVISA) issued proposed rules concerning patents and are sifting through public comments to determine how they will deal with biotech patents. A quirk in Brazilian law requires that the health regulatory authority (ANVISA) must provide “prior consent” on the grant of a pharmaceutical patent.  Traditionally, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Brazilian Attorney General of the Union restricts ANVISA’s role in pharmaceutical patent review

We are receiving reports from Brazil that the Brazilian Attorney General of the Union (AGU) has adopted a position restricting the role of the National Agency for Sanitary Surveillance (ANVISA) in the patenting process for pharmaceutical products and processes.  Due to a lack of clarity in the Industrial Property Law, ANVISA has used its prior consent role to reject patent applications on the basis of novelty and inventiveness which is officially the role of the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,